← All Vericel CORP filings

Vericel CORP DEF 14A proxy statements

Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.

NASDAQ
VCEL
Vericel CORP
DEF: Vericel Reports Record 2025 Revenue, Strong Profit Growth
Vericel Corporation achieved record full-year revenue of $276.3 million in 2025, marking its second consecutive year of GAAP profitability and significant growth across its product portfolio.
NASDAQ
VCEL
Vericel CORP
DEFA14A: Vericel Corporation Sets Date for 2025 Annual Shareholder Meeting, Outlines Key Proposals
Vericel Corporation announces its 2025 Annual Meeting of Shareholders to be held virtually on April 30, 2025, with several key proposals for shareholder vote.
NASDAQ
VCEL
Vericel CORP
DEF: Vericel Delivers Strong 2024 Financial Results, Eyes Continued Growth in 2025
Vericel Corporation reports strong financial and business results for 2024, driven by revenue growth and profitability improvements, and anticipates continued growth in 2025.
NASDAQ
VCEL
Vericel CORP
DEFA14A: Vericel Corporation Sets Date for 2024 Annual Shareholder Meeting
Vericel Corporation announces its 2024 Annual Meeting of Shareholders to be held virtually on May 1, 2024, with voting open until April 30, 2024.
NASDAQ
VCEL
Vericel CORP
DEF 14A: Vericel Reports Strong 2023 Results, Anticipates Continued Growth in 2024
Vericel Corporation announces a strong financial year in 2023, with significant revenue growth and key business milestones, setting the stage for continued success in 2024.